New Products for Pharmacists: Rx, OTC, and generics (January 2011)

January 15, 2011

A survey of new Rx, new generic, and new OTC products

Key Points

RX CARE

New drugs

Forest Laboratories' Teflaro (ceftaroline fosamil), a broad-spectrum bactericidal cephalosporin with activity against both gram-positive and gram-negative microorganisms, was approved by FDA for treatment of community-acquired bacterial pneumonia (CABP), including cases caused by Streptococcus pneumoniae bacteremia, and acute bacterial skin and skin structure infection (ABSSSI), including cases caused by methicillin-resistant Staphylococcus aureus (MRSA). ( http://www.FRX.com/)

FDA approved Axiron (testosterone topical solution), from Eli Lilly and Acrux Pharma for replacement therapy in men aged ≥18 years for conditions associated with a deficiency or absence of endogenous testosterone. ( http://www.lilly.com/ / 800-545-5979)

FDA approved Avanir Pharmaceuticals' Nuedexta (dextromethorphan hydrobromide and quinidine sulfate) capsules as the first treatment for pseudobulbar affect (PBA). ( http://www.avanir.com/)

OCuSoft's Zytaze (zinc citrate and phytase) has been approved as a medical food providing nutritional support to enhance the effectiveness of botulinum toxin injections in the treatment of blepharospasm, hemifacial spasm, or facial cosmetic procedures. ( http://www.zytaze.com/ / 800-233-5469)